Rockwell Medical (NASDAQ:RMTI) Now Covered by StockNews.com

StockNews.com started coverage on shares of Rockwell Medical (NASDAQ:RMTIGet Rating) in a report issued on Thursday. The brokerage set a “hold” rating on the stock.

A number of other equities research analysts have also issued reports on RMTI. Zacks Investment Research raised shares of Rockwell Medical from a “sell” rating to a “hold” rating in a report on Thursday, March 17th. HC Wainwright cut their target price on shares of Rockwell Medical from $5.00 to $3.00 and set a “buy” rating for the company in a report on Tuesday, January 18th.

Shares of RMTI opened at $0.34 on Thursday. The company has a debt-to-equity ratio of 5.21, a current ratio of 1.68 and a quick ratio of 1.49. Rockwell Medical has a 1 year low of $0.30 and a 1 year high of $1.06. The company has a 50 day simple moving average of $0.37 and a two-hundred day simple moving average of $0.41. The firm has a market cap of $32.33 million, a P/E ratio of -1.01 and a beta of 1.09.

Several hedge funds have recently bought and sold shares of the stock. Marshall Wace LLP purchased a new position in shares of Rockwell Medical in the first quarter valued at $57,000. Metropolitan Life Insurance Co NY bought a new stake in Rockwell Medical in the first quarter worth $106,000. Verdence Capital Advisors LLC lifted its position in Rockwell Medical by 25.1% in the fourth quarter. Verdence Capital Advisors LLC now owns 443,545 shares of the company’s stock worth $182,000 after buying an additional 88,980 shares during the last quarter. Renaissance Technologies LLC lifted its position in Rockwell Medical by 81.1% in the fourth quarter. Renaissance Technologies LLC now owns 225,534 shares of the company’s stock worth $92,000 after buying an additional 101,000 shares during the last quarter. Finally, Perkins Capital Management Inc. lifted its position in Rockwell Medical by 34.5% in the fourth quarter. Perkins Capital Management Inc. now owns 2,957,025 shares of the company’s stock worth $1,212,000 after buying an additional 758,400 shares during the last quarter. 27.88% of the stock is owned by hedge funds and other institutional investors.

Rockwell Medical Company Profile (Get Rating)

Rockwell Medical, Inc operates as a biopharmaceutical company that targets end-stage renal disease and chronic kidney disease with therapies and products for the treatment of iron deficiency and hemodialysis in the United States and internationally. The company offers Triferic Dialysate and Triferic AVNU, an iron therapy that replaces iron and maintains hemoglobin in dialysis patients without increasing iron stores.

Featured Stories

Receive News & Ratings for Rockwell Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rockwell Medical and related companies with MarketBeat.com's FREE daily email newsletter.